New drug ITC-6146RO enters first human tests for tough cancers
NCT ID NCT07423117
First seen Mar 01, 2026 · Last updated Jun 22, 2026 · Updated 16 times
Summary
This early-phase trial tests an experimental drug called ITC-6146RO in about 102 adults with advanced or metastatic cancers (like prostate, lung, or breast cancer) that have not improved with standard treatments. The study has two parts: first, finding a safe dose, then checking how well the drug works and its side effects. The main goal is safety, not yet a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ITC-6146RO (an experimental drug given by IV infusion)
What this could lead to
If this works, it could point toward a new treatment option for people with advanced cancers that have not responded to standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 102 participants, so the drug may not work or could have serious side effects. It is too soon to know if it will help patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.